Traduction de «clinical use of mesenchymal » (Néerlandais → Français) :

Clinical use of mesenchymal stem cells for the prevention and treatment of graft rejection and graft-versus-host disease after allogeneic transplantation for hematologic malignancies
Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after nonmyeloablative conditioning: a phase II randomized double-blind study.

Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission
Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission

The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.
The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

clinical trials with veterinary medicines and medical devices for veterinary use ●● Reduction of the backlogs for veterinary
clinical trials with veterinary medicines and medical devices for veterinary use ●● Reduction of the backlogs for veterinary

Geneesk. 32, 1547-1550 (2001) National Institute for Clinical Excellence: NICE issues guidance on rosiglitazone for type 2 diabetes en NICE issues guidance on the use of pioglitazone for type 2 diabetes mellitus. [http ...]
Geneesk. 32, 1547-1550 (2001) National Institute for Clinical Excellence: NICE issues guidance on rosiglitazone for type 2 diabetes et NICE issues guidance on the use of pioglitazone for type 2 diabetes mellitus. [http ...]

" Using indicators in reports on clinical pharmacy services: what, why and how?" , introductie door P. Tulkens (UCL) en I. Spriet (UZ Leuven)
" Using indicators in reports on clinical pharmacy services: what, why and how?" , introduction par P. Tulkens (UCL) et I. Spriet (UZ Leuven)

Nagy Z, Chang C, Shapiro D, Bernal D, Elsner C, Mitchel-Leef D, et al. Clinical evauation of the efficiency of an oocyte donation program using egg cryo-banking Fertil Steril 2009; 92:520-6.
Nagy Z, Chang C, Shapiro D, Bernal D, Elsner C, Mitchel-Leef D, et al. Clinical evauation of the efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril 2009; 92:520-6.

5. “Clinical use of red cells in critical patients: Surgery & Intensive Care” (Ph.
5. « Clinical use of red cells in critical patients: Surgery & Intensive Care » (Ph.

2. “Clinical use of red cells in critical patients: Surgery & Intensive Care” (Ph.
2. « Clinical use of red cells in critical patients: Surgery & Intensive Care » (Ph.